|
| 36861661 | An evaluation of adverse drug reactions and outcomes attributed to kratom in the US Food and Drug Administration Adverse Event Reporting System from January 2004 through September 2021. | Clin Transl Sci | 2023 |
| 37541764 | An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations. | J Pharmacol Exp Ther | 2023 |
| 37502215 | Potential pharmacokinetic interactions with concurrent use of herbal medicines and a ritonavir-boosted COVID-19 protease inhibitor in low and middle-income countries. | Front Pharmacol | 2023 |
| 37639334 | Co-consuming green tea with raloxifene decreases raloxifene systemic exposure in healthy adult participants. | Clin Transl Sci | 2023 |
| 37286363 | Translating Kratom-Drug Interactions: From Bedside to Bench and Back. | Drug Metab Dispos | 2023 |
| 37313955 | Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. | Clin Pharmacol Ther | 2023 |
| 37042268 | Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults. | Int J Clin Pharmacol Ther | 2023 |
| 36972999 | A Physiologically-Based Pharmacokinetic Model for Cannabidiol in Healthy Adults, Hepatically-Impaired Adults, and Children. | Drug Metab Dispos | 2023 |
| 36924284 | Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom. | Clin Pharmacol Ther | 2023 |
| 36780161 | Assessment of Orally Administered ο9-Tetrahydrocannabinol When Coadministered With Cannabidiol on ο9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial. | JAMA Netw Open | 2023 |
| 36645711 | Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic Approach. | Ther Drug Monit | 2023 |
| 36933632 | Developing a Knowledge Graph for Pharmacokinetic Natural Product-Drug Interactions. | J Biomed Inform | 2023 |
| 34784423 | Cannabis for Medical Use: Clinical Pharmacology Perspectives on Scientific and Regulatory Challenges. | Clin Pharmacol Ther | 2022 |
| 35115300 | Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes. | Drug Metab Dispos | 2022 |
| 35335999 | Clinical Pharmacokinetic Assessment of Kratom (<i>Mitragyna speciosa</i>), a Botanical Product with Opioid-like Effects, in Healthy Adult Participants. | Pharmaceutics | 2022 |
| 35165231 | A Case of Potential Pharmacokinetic Kratom-drug Interactions Resulting in Toxicity and Subsequent Treatment of Kratom Use Disorder With Buprenorphine/Naloxone. | J Addict Med | 2022 |
| 34699676 | Adapting regulatory drug-drug interaction guidance to design clinical pharmacokinetic natural product-drug interaction studies: A NaPDI Center recommended approach. | Clin Transl Sci | 2022 |
| 32460379 | Intestinal P-gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications. | Clin Pharmacol Ther | 2021 |
| 33712517 | Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach. | Pharmacol Rev | 2021 |
| 33587330 | Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions. | Phytother Res | 2021 |
| 34006613 | Erratum for Herring et al., "Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs". | Antimicrob Agents Chemother | 2021 |
| 33174626 | Assessing Transporter-Mediated Natural Product-Drug Interactions Via In vitro-In Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail. | Clin Pharmacol Ther | 2021 |
| 33093187 | Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations. | J Pharmacol Exp Ther | 2021 |
| 33468464 | Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs. | Antimicrob Agents Chemother | 2021 |
| 32197968 | "Natural" is not synonymous with "Safe": Toxicity of natural products alone and in combination with pharmaceutical agents. | Regul Toxicol Pharmacol | 2020 |
| 33154449 | Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions. | Sci Rep | 2020 |
| 32601103 | A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies. | Drug Metab Dispos | 2020 |
| 32591416 | Modulation of Major Human Liver Microsomal Cytochromes P450 by Component Alkaloids of Goldenseal: Time-Dependent Inhibition and Allosteric Effects. | Drug Metab Dispos | 2020 |
| 32816868 | Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions. | Drug Metab Dispos | 2020 |
| 32587099 | Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. | Drug Metab Dispos | 2020 |
| 32140423 | United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. | Toxicol Rep | 2020 |
| 30387917 | Effects of Common CYP1A2 Genotypes and Other Key Factors on Intraindividual Variation in the Caffeine Metabolic Ratio: An Exploratory Analysis. | Clin Transl Sci | 2019 |
| 31407329 | The Age of Omics-Driven Precision Medicine. | Clin Pharmacol Ther | 2019 |
| 31420525 | A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model. | J Pharmacol Exp Ther | 2019 |
| 31071346 | A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. | Pharmacol Ther | 2019 |
| 31028057 | Indinavir Increases Midazolam <i>N</i>-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach. | Drug Metab Dispos | 2019 |
| 30849452 | Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity. | Toxicon | 2019 |
| 30681109 | Selection and characterization of botanical natural products for research studies: a NaPDI center recommended approach. | Nat Prod Rep | 2019 |
| 29735752 | Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach. | Drug Metab Dispos | 2018 |
| 30151884 | "Green Medicine": The Past, Present, and Future of Botanicals. | Clin Pharmacol Ther | 2018 |
| 30170118 | Follow that botanical: Challenges and recommendations for assessing absorption, distribution, metabolism and excretion of botanical dietary supplements. | Food Chem Toxicol | 2018 |
| 30815066 | Developing User Personas to Aid in the Design of a User-Centered Natural Product-Drug Interaction Information Resource for Researchers. | AMIA Annu Symp Proc | 2018 |
| 29467215 | Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (<i>Camellia sinensis)</i> Using a Biochemometric Approach: Application to Raloxifene as a Test Drug via In Vitro to In Vivo Extrapolation. | Drug Metab Dispos | 2018 |
| 29761830 | ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision. | Clin Pharmacol Ther | 2018 |
| 29735755 | Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary. | Drug Metab Dispos | 2018 |
| 28032362 | Prioritizing pharmacokinetic drug interaction precipitants in natural products: application to OATP inhibitors in grapefruit juice. | Biopharm Drug Dispos | 2017 |
| 28453261 | Comparison of Metabolomics Approaches for Evaluating the Variability of Complex Botanical Preparations: Green Tea (Camellia sinensis) as a Case Study. | J Nat Prod | 2017 |
| 28318023 | Therapeutic disasters that hastened safety testing of new drugs. | Clin Pharmacol Ther | 2017 |
| 28504483 | Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. | Clin Transl Sci | 2017 |
| 26776752 | Assessing Natural Product-Drug Interactions: An End-to-End Safety Framework. | Regul Toxicol Pharmacol | 2016 |